ACP does not support QPP measure 283: "Dementia: Neuropsychiatric Symptom Assessment." Although this practice may help clinicians determine appropriate management of patients with dementia, there is a lack of high-quality evidence examining the impact of assessment on clinical outcomes or on appropriate assessment intervals. Also, implementation may result in overuse of pharmacologic therapy. Non-pharmacologic treatment modalities exist to manage neuropsychiatric symptoms, but implementation requires caregiver involvement. Furthermore, the numerator details do not clearly specify a structured process for documentation of neuropsychiatric symptom assessment and the measure developers do not describe any reliability or validity data in the measure report.